Attached files
| file | filename |
|---|---|
| EX-99.1 - ENZON PHARMACEUTICALS, INC. | c65749_ex99-1.htm |
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 | ||
| FORM 8-K CURRENT REPORT | ||
| Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 | ||
| Date of Report (Date of earliest event reported): May 19, 2011 | ||
| ENZON PHARMACEUTICALS, INC. | ||
| (Exact name of registrant as specified in its charter) | ||
| Delaware |
0-12957 |
22-2372868 |
| (State or other jurisdiction of incorporation) |
(Commission File Number) |
(IRS Employer Identification No.) |
| 20 Kingsbridge Road, Piscataway, New Jersey | 08854 | |
| (Address of principal executive offices) | (Zip Code) |
| (732) 980-4500 | ||
| (Registrant’s telephone number, including area code) | ||
|
Not Applicable Check the appropriate box below if the
Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: |
Item 8.01 Other Events.
On May 19, 2011, Enzon Pharmaceuticals, Inc. (the “Company”) issued a press release announcing that in light of evolving standards of care for the treatment of metastatic colorectal cancer (mCRC), the Company will discontinue its PEG-SN38 (EZN-2208) clinical program in this disease, following conclusion of its Phase II study.
A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
The following exhibit is furnished herewith:
|
Exhibit No.
|
Description
| |
| 99.1 | Press Release of Enzon Pharmaceuticals, Inc. dated May 19, 2011 | |
SIGNATURES
Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| ENZON PHARMACEUTICALS, INC. | ||||||
| (Registrant) | ||||||
| Date: | May 19, 2011 | By: /s/ Andrew Rackear | ||||
| Name: | Andrew Rackear | |||||
| Title: | Vice President and General Counsel | |||||
EXHIBIT INDEX
|
Exhibit No.
|
Description
| |
| 99.1 | Press Release of Enzon Pharmaceuticals, Inc. dated May 19, 2011 | |